Press coverage about Ekso Bionics (NASDAQ:EKSO) has been trending somewhat positive on Thursday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ekso Bionics earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.4069929700524 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Rehabilitation Devices Market Trends, Revenue, Market Share and Growth Rate (emailwire.com)
- Zacks: Ekso Bionics Holdings Inc (EKSO) Given $3.00 Consensus Target Price by Brokerages (americanbankingnews.com)
- Artificial Organ Bank Market Is Anticipated to Grow $45.18 Billion by 2022 (digitaljournal.com)
- Rehabilitation Robots Market to 2025 – Ekso Bionics, Hocoma, Interactive Motion Technologies (emailwire.com)
EKSO traded down $0.05 during trading on Thursday, reaching $2.44. The company’s stock had a trading volume of 2,100 shares, compared to its average volume of 1,728,320. Ekso Bionics has a 52-week low of $1.02 and a 52-week high of $4.77. The firm has a market capitalization of $163.03 million, a PE ratio of -2.73 and a beta of -0.36. The company has a current ratio of 2.17, a quick ratio of 1.92 and a debt-to-equity ratio of 0.49.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02). The firm had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $3.03 million. Ekso Bionics had a negative return on equity of 169.75% and a negative net margin of 327.12%. sell-side analysts predict that Ekso Bionics will post -0.44 EPS for the current year.
A number of equities research analysts have weighed in on EKSO shares. ValuEngine raised Ekso Bionics from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. Zacks Investment Research raised Ekso Bionics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Thursday, July 19th.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Featured Article: Penny Stocks
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.